Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02511184
Title Crizotinib Plus Pembrolizumab In Alk-positive Advanced Non Small Cell Lung Cancer Patients
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Pfizer
Indications

lung non-small cell carcinoma

Therapies

Crizotinib

Pembrolizumab

Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST